Form 20 – IPG Reprogramming Device Q8-Q9 in Refractory Overactive Bladder: Sacral Neuromodulation v. Botulinum Toxin Assessment

Form 20 – IPG Reprogramming Device Q8-Q9, CSV
Study Description
The purpose of this randomized, open-label, active-control trial was to compare the effectiveness of intra-detrusor botulinum toxin A (Botox A®, Allergan) versus sacral neuromodulation (InterStim®, Medtronic) for the treatment of refractory urge urinary incontinence. In addition, the study evaluated select technical attributes of the interventions as well as the effect of these two interventions on other lower urinary tract and pelvic floor symptoms. Non-pregnant adult females at least 21 years old with refractory urinary urge incontinence

表单20——可植入脉冲发生器（Implantable Pulse Generator，IPG）重编程设备Q8-Q9，逗号分隔值（Comma-Separated Values，CSV）文件
研究概况
本项随机、开放标签、阳性对照临床试验旨在对比膀胱内注射A型肉毒杆菌毒素（保妥适A®（Botox A®，艾尔建（Allergan）））与骶神经调控疗法（InterStim®，美敦力（Medtronic））治疗难治性急迫性尿失禁的有效性。此外，本研究还评估了上述两种干预措施的部分技术属性，以及它们对其他下尿路及盆底症状的影响。受试对象为年龄≥21岁的非妊娠成年女性难治性急迫性尿失禁患者。